SCHEMBL13720585

SCHEMBL13720585

N#Cc1ccc(S(=O)(=O)c2nn(NC(=O)Cc3ccc(F)cc3)c(=O)c3ccccc23)cc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.40
▸ LMNA P02545 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ USP2 O75604 1/20 0.40
▸ EGFR P00533 7/20 0.39
▸ ERBB2 P04626 7/20 0.39
▸ MAPT P10636 2/20 0.39
▸ CA12 O43570 2/20 0.38
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ CA9 Q16790 2/20 0.38
▸ ABCB1 P08183 1/20 0.38
▸ RAB9A P51151 1/20 0.37
▸ PLK1 P53350 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ KEAP1 Q14145 1/20 0.36
▸ NFE2L2 Q16236 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13720697 0.92 ABCB1 (0.35) ALDH1A1LMNASMN1; SMN2USP2MAPT
SCHEMBL13720642 0.91 ABCB1 (0.48) ALDH1A1EGFRERBB2CA12CA1
SCHEMBL13721251 0.89 EGFR (0.50) ALDH1A1LMNASMN1; SMN2USP2EGFR
SCHEMBL13720767 0.80 MAPK8 (0.42) ALDH1A1LMNACA12CA1CA2
SCHEMBL13720795 0.80 AKR1B1 (0.39) LMNASMN1; SMN2USP2EGFRERBB2
SCHEMBL13720726 0.79 EGFR (0.50) EGFRERBB2MEN1KMT2A
SCHEMBL13721332 0.79 EGFR (0.50) ALDH1A1LMNAEGFRERBB2CA12
SCHEMBL13720548 0.79 AKR1B1 (0.41) LMNASMN1; SMN2USP2EGFRERBB2
SCHEMBL13721362 0.79 KEAP1 (0.37) ALDH1A1SMN1; SMN2MAPTABCB1RAB9A
SCHEMBL13720284 0.78 EGFR (0.50) ALDH1A1EGFRERBB2MAPTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859549-B2 Potassium channel modulators ABBVIE, INC. (US) 2014-10-14 — — US claimed
WO-2012158399-A1 CONDENSED 2 - CARBAMOYLPYRIDAZINONES AS POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-11-22 — — WO claimed
US-20120289500-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-11-15 — — US claimed
US-8859549-B2 Potassium channel modulators ABBVIE, INC. (US) 2014-10-14 — — US disclosed
WO-2012158399-A1 CONDENSED 2 - CARBAMOYLPYRIDAZINONES AS POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-11-22 — — WO disclosed
US-20120289500-A1 POTASSIUM CHANNEL MODULATORS ABBOTT LABORATORIES (US) 2012-11-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289500-A1 POTASSIUM CHANNEL MODULATORS KCNQ1, KCNQ2, KCNJ2 ALDH1A1 743/4885LMNA 1022/4885SMN1; SMN2 1602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback